News

Alembic Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 15 May 2026, inter alia, have recommended the final dividend of Rs 12 per equity Share (i.e. 600%) , subject to the approval of the shareholders.

Net profit of Alembic Pharmaceuticals rose 29.20% to Rs 202.70 crore in the quarter ended March 2026 as against Rs 156.89 crore during the previous quarter ended March 2025. Sales rose 4.41% to Rs 1847.72 crore in the quarter ended March 2026 as against Rs 1769.64 crore during the previous quarter ended March 2025.For the full year,net profit rose 15.66% to Rs 674.77 crore in the year ended March 2026 as against Rs 583.42 crore during the previous year ended March 2025. Sales rose 10.08% to Rs 7344.90 crore in the year ended March 2026 as against Rs 6672.08 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales1847.721769.64 4 7344.906672.08 10 OPM %12.3415.33 -15.2315.11 - PBDT231.97260.93 -11 1079.49972.89 11 PBT143.38191.94 -25 760.94694.31 10 NP202.70156.89 29 674.77583.42 16 Powered by Capital Market - Live News

Alembic Pharmaceuticals has received an Establishment Inspection Report (EIR) from the USFDA, for its Injectable facility (F-III) located at Karakhadi on 13 May 2026. The USFDA inspection was conducted from 9 February 2026 to 18 February 2026.

Alembic Pharmaceuticals (Alembic) today announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Darolutamide Tablets, 300 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Nubeqa Tablets, 300 mg, of Bayer HealthCare Pharmaceuticals Inc. (Bayer). Darolutamide is an androgen receptor inhibitor indicated for the treatment of adult patients with: i) non-metastatic castration-resistant prostate cancer (nmCRPC), ii) metastatic castration-sensitive prostate cancer (mCSPC), and iii) metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel. Refer label for a detailed indication.

Alembic Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 15 May 2026.